Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McGill University

$27,000.00

Development of a cross-species vaccine against Schistosoma species

FY 2025-26

Summary
Schistosomiasis, also known as bilharzia or snail fever, is a neglected parasitic disease that affects more than 200 million people worldwide, mainly in rural parts of sub-Saharan Africa but hybrid species are on the rise and have also been recorded in Europe. It is caused by blood fluke of the genus Schistosoma that infects people through skin contact due to contaminated water. Two of the main species that infect humans are: Schistosoma mansoni which affects the liver and intestines, and Schistosoma haematobium which targets the bladder and reproductive organs. Repeated exposure and infection damages tissues and organs due to the deposition of parasitic eggs. In women, S. haematobium can cause female genital schistosomiasis (FGS), which causes inflammatory lesions and disrupts mucosal barriers in the reproductive organs, increasing the risk of HIV infection as well as HPV. The only available treatment is a drug named praziquantel, which kills adult worms but does not prevent reinfection or treat late-stage FGS complications. Because many people are repeatedly exposed, a preventive vaccine is urgently needed. Our research focuses on developing a vaccine that could protect against multiple Schistosoma species. Our lab studies a parasite enzyme called cathepsin B (or SmCB), which the worms use to digest host blood proteins. Since this enzyme is very similar across different Schistosoma species, SmCB may trigger immune protection against several of them, specifically those present in overlapping geographical regions. We will measure worm and egg counts, immune responses, and tissue inflammation to assess vaccine effectiveness. A cross-species vaccine has the potential to improve millions of lives by reducing transmission, morbidity and social stigma.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
573123
Name
Bedos Anne-Sophie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a cross-species vaccine against Schistosoma species
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cross-Protection; Immunity; Prime And Boost; Schistosoma Haematobium; Schistosoma Mansoni; Schistosomiasis
Abstract
Schistosomiasis, also known as bilharzia or snail fever, is a neglected parasitic disease that affects more than 200 million people worldwide, mainly in rural parts of sub-Saharan Africa but hybrid species are on the rise and have also been recorded in Europe. It is caused by blood fluke of the genus Schistosoma that infects people through skin contact due to contaminated water. Two of the main species that infect humans are: Schistosoma mansoni which affects the liver and intestines, and Schistosoma haematobium which targets the bladder and reproductive organs. Repeated exposure and infection damages tissues and organs due to the deposition of parasitic eggs. In women, S. haematobium can cause female genital schistosomiasis (FGS), which causes inflammatory lesions and disrupts mucosal barriers in the reproductive organs, increasing the risk of HIV infection as well as HPV. The only available treatment is a drug named praziquantel, which kills adult worms but does not prevent reinfection or treat late-stage FGS complications. Because many people are repeatedly exposed, a preventive vaccine is urgently needed. Our research focuses on developing a vaccine that could protect against multiple Schistosoma species. Our lab studies a parasite enzyme called cathepsin B (or SmCB), which the worms use to digest host blood proteins. Since this enzyme is very similar across different Schistosoma species, SmCB may trigger immune protection against several of them, specifically those present in overlapping geographical regions. We will measure worm and egg counts, immune responses, and tissue inflammation to assess vaccine effectiveness. A cross-species vaccine has the potential to improve millions of lives by reducing transmission, morbidity and social stigma.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bedos, Anne-Sophie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~